頁籤選單縮合
題名 | 探討目前肺動脈高血壓之治療與預後=Current Therapy of Pulmonary Hypertension |
---|---|
作者姓名(中文) | 黃建衡; 黃清國; 施嘉慶; 李威; 王茂富; | 書刊名 | 藥學雜誌 |
卷期 | 26:3=104 2010.09[民99.09] |
頁次 | 頁29-35 |
分類號 | 415.382 |
關鍵詞 | 肺動脈高血壓; 內皮素接受體拮抗劑; 磷酸二酯酶第五型抑制劑; PAH; ERA; PED5-I; |
語文 | 中文(Chinese) |
中文摘要 | 肺動脈高血壓是一種漸進式且致命性的疾病而且其預後普遍較差,升高的肺動脈壓、肺部血管阻力以及肺部血管重新塑型可能會導致右心室肥大甚至右心衰竭,而這些因素都有可能增加病患的危險性及死亡率。儘管目前肺動脈高血壓確切的機轉還有待更進一步之釐清,但是肺部中許多內生性物質之間的失衡已被確定。傳統對抗肺動脈高血壓的藥物已有抗凝血劑、鈣離子阻斷劑、利尿劑、強心劑,但仍需發展更多的治療藥物及其複合療法,因為此一疾病的死亡率依然相當的高。近年實證醫學相關研究指出,內皮素接受體拮抗劑、磷酸二酯酶第五型抑制劑以及環前列腺素可用於治療肺動脈高血壓,另一方面,許多相關系列的實驗及研究亦指出血清素系統和 Rho激酶可能是未來發展肺動脈高血壓藥物新的方向。 |
英文摘要 | Pulmonary arterial hypertension(PAH)is a progressive and fatal disease with poor prognosis. PAH, characterized by an progressive elevation of pulmonary arterial pressure, vascular resistance and vascular remodeling which may cause right ventricular hypertrophy, heart failure, and increases mortality of patients. However, the precise mechanism of PAH still remains to be elucidated, but an imbalance between vasoconstrictor/proliferative agents(e.g. endothelin)and vasodilator/ antiproliferative substances(e.g. prostacyclin and nitric oxide)have been identified in the lung vasculature. Although anticoagulant agents, calcium channel blocker, diuretics, and inotropic agent are currently used for treatment of PAH, more effective treatment or combination therapy needs to be developed. Recent Evidence-based medicine suggests that endothelin receptor antagonists(ERA), phosphodiesterase type V inhibitor(PDE5-I) and prostacyclin may be promising drugs in the treatment of pulmonary arterial hypertension. In addition, series of experimental and clinical studies suggested that serotonin system and Rho kinase is an attractive target for the development of therapeutics to treat PAH. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。